Sam Serafi, MD
Rheumatology · Baltimore, MDNPI 1538427588
Payments from drug & device makers
Across 176 payments — averaging $18.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$555
- AbbVie$417
- Novartis$353
- Johnson & Johnson$306
- E.r. Squibb & Sons, L.L.C.$217
- Pfizer$205
- plus $1K from 22 others
What the payments were for
- Food & beverage$3,12696%
- Education$1154%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 27 | $555 |
| AbbVie | 30 | $417 |
| Novartis | 17 | $353 |
| Johnson & Johnson(2 entities) | 10 | $306 |
| E.r. Squibb & Sons, L.L.C. | 14 | $217 |
| Pfizer | 16 | $205 |
| UCB, Inc. | 8 | $170 |
| GSK | 8 | $149 |
| Boehringer Ingelheim | 4 | $111 |
| Lilly USA, LLC | 7 | $110 |
| Radius Health, Inc. | 5 | $107 |
| Regeneron Healthcare Solutions, Inc. | 4 | $80 |
| Bristol Myers Squibb | 4 | $80 |
| Aurinia Pharma U.S., Inc. | 3 | $72 |
| Mallinckrodt Enterprises LLC | 2 | $45 |
| AstraZeneca(2 entities) | 2 | $43 |
| Hikma Pharmaceuticals USA | 3 | $38 |
| Invivyd Inc | 1 | $26 |
| Mallinckrodt Hospital Products Inc. | 1 | $22 |
| Merck | 1 | $19 |
| Sanofi | 1 | $17 |
| Qiagen, LLC | 1 | $16 |
| Actelion Pharmaceuticals US, Inc. | 1 | $16 |
| Bioventus LLC | 1 | $15 |
| Pacira Therapeutics, Inc. | 1 | $15 |
| Antares Pharma, Inc. | 1 | $14 |
| Medexus Pharma, Inc. | 1 | $12 |
| Fidia Pharma USA Inc. | 2 | $8 |
How this compares
$3,241 in reported general payments places this provider in the 50th percentile of 173 rheumatology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 62 | $479,841 |
| Humira(Cf) PenAdalimumab | 28 | $263,031 |
| Enbrel MiniEtanercept | 23 | $196,022 |
| Orencia ClickjectAbatacept | 15 | $83,683 |
| Actemra ActpenTocilizumab | 13 | $60,629 |
| Duloxetine Hcl | 213 | $5,719 |
| MethotrexateMethotrexate Sodium | 121 | $5,383 |
| Atovaquone | 17 | $5,175 |
| Hydroxychloroquine Sulfate | 130 | $4,798 |
| Leflunomide | 37 | $2,644 |
| Cevimeline Hcl | 15 | $2,272 |
| Prednisone | 163 | $1,495 |
| Colchicine | 13 | $1,173 |
| Gabapentin | 53 | $1,056 |
| Allopurinol | 52 | $1,000 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Baltimore
- Thomas Grader BeckBaltimore$1.2M
- Michelle PetriBaltimore$1.1M
- Laura HummersBaltimore$1M
- Lisa ChristopherBaltimore$370K
- Violeta RusBaltimore$358K
- Ami ShahBaltimore$347K
- Alan BaerBaltimore$277K
- Clifton BinghamBaltimore$210K
- Homa TimlinBaltimore$152K
- Marc HochbergBaltimore$140K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.